Salvage therapy with tigecycline for recurrent infection caused by ertapenem-resistant extended-spectrum β-lactamase-producing Klebsiella pneumoniae

Po-Lin Chen, Jing Jou Yan, Chi Jung Wu, Hsin Chun Lee, Chia-Ming Chang, Nan-Yao Lee, Nai-Ying Ko, Li Rong Wang, Hsin-I Shih, Ching Chi Lee, Wen-Chien Ko

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Optimal antimicrobial therapy for infections due to ertapenem-resistant Enterobacteriaceae remains undetermined. In this study, a diabetic patient with recurrent pyomyositis and osteomyelitis caused by extended-spectrum β-lactamase (ESBL)-producing Klebsiella pneumoniae developed ertapenem resistance after imipenem/cilastatin treatment, which was a currently recommended therapy. He was finally treated successfully using tigecycline. Ertapenem resistance was in part explained by the production of SHV-type ESBL and the absence of an outer membrane protein, OmpK36. Our observation suggests that tigecycline may be an alternative for invasive infections caused by ESBL-producing Enterobacteriaceae with decreased susceptibility to carbapenem.

Original languageEnglish
Pages (from-to)312-314
Number of pages3
JournalDiagnostic Microbiology and Infectious Disease
Volume68
Issue number3
DOIs
Publication statusPublished - 2010 Nov 1

Fingerprint

Salvage Therapy
Klebsiella pneumoniae
Enterobacteriaceae
Infection
Pyomyositis
Carbapenems
Osteomyelitis
Membrane Proteins
Therapeutics
Observation
ertapenem
tigecycline

All Science Journal Classification (ASJC) codes

  • Microbiology (medical)
  • Infectious Diseases

Cite this

@article{5b3eac69ce8c42d6b1f8cf595017e519,
title = "Salvage therapy with tigecycline for recurrent infection caused by ertapenem-resistant extended-spectrum β-lactamase-producing Klebsiella pneumoniae",
abstract = "Optimal antimicrobial therapy for infections due to ertapenem-resistant Enterobacteriaceae remains undetermined. In this study, a diabetic patient with recurrent pyomyositis and osteomyelitis caused by extended-spectrum β-lactamase (ESBL)-producing Klebsiella pneumoniae developed ertapenem resistance after imipenem/cilastatin treatment, which was a currently recommended therapy. He was finally treated successfully using tigecycline. Ertapenem resistance was in part explained by the production of SHV-type ESBL and the absence of an outer membrane protein, OmpK36. Our observation suggests that tigecycline may be an alternative for invasive infections caused by ESBL-producing Enterobacteriaceae with decreased susceptibility to carbapenem.",
author = "Po-Lin Chen and Yan, {Jing Jou} and Wu, {Chi Jung} and Lee, {Hsin Chun} and Chia-Ming Chang and Nan-Yao Lee and Nai-Ying Ko and Wang, {Li Rong} and Hsin-I Shih and Lee, {Ching Chi} and Wen-Chien Ko",
year = "2010",
month = "11",
day = "1",
doi = "10.1016/j.diagmicrobio.2010.06.009",
language = "English",
volume = "68",
pages = "312--314",
journal = "Diagnostic Microbiology and Infectious Disease",
issn = "0732-8893",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Salvage therapy with tigecycline for recurrent infection caused by ertapenem-resistant extended-spectrum β-lactamase-producing Klebsiella pneumoniae

AU - Chen, Po-Lin

AU - Yan, Jing Jou

AU - Wu, Chi Jung

AU - Lee, Hsin Chun

AU - Chang, Chia-Ming

AU - Lee, Nan-Yao

AU - Ko, Nai-Ying

AU - Wang, Li Rong

AU - Shih, Hsin-I

AU - Lee, Ching Chi

AU - Ko, Wen-Chien

PY - 2010/11/1

Y1 - 2010/11/1

N2 - Optimal antimicrobial therapy for infections due to ertapenem-resistant Enterobacteriaceae remains undetermined. In this study, a diabetic patient with recurrent pyomyositis and osteomyelitis caused by extended-spectrum β-lactamase (ESBL)-producing Klebsiella pneumoniae developed ertapenem resistance after imipenem/cilastatin treatment, which was a currently recommended therapy. He was finally treated successfully using tigecycline. Ertapenem resistance was in part explained by the production of SHV-type ESBL and the absence of an outer membrane protein, OmpK36. Our observation suggests that tigecycline may be an alternative for invasive infections caused by ESBL-producing Enterobacteriaceae with decreased susceptibility to carbapenem.

AB - Optimal antimicrobial therapy for infections due to ertapenem-resistant Enterobacteriaceae remains undetermined. In this study, a diabetic patient with recurrent pyomyositis and osteomyelitis caused by extended-spectrum β-lactamase (ESBL)-producing Klebsiella pneumoniae developed ertapenem resistance after imipenem/cilastatin treatment, which was a currently recommended therapy. He was finally treated successfully using tigecycline. Ertapenem resistance was in part explained by the production of SHV-type ESBL and the absence of an outer membrane protein, OmpK36. Our observation suggests that tigecycline may be an alternative for invasive infections caused by ESBL-producing Enterobacteriaceae with decreased susceptibility to carbapenem.

UR - http://www.scopus.com/inward/record.url?scp=77957905891&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77957905891&partnerID=8YFLogxK

U2 - 10.1016/j.diagmicrobio.2010.06.009

DO - 10.1016/j.diagmicrobio.2010.06.009

M3 - Article

C2 - 20846813

AN - SCOPUS:77957905891

VL - 68

SP - 312

EP - 314

JO - Diagnostic Microbiology and Infectious Disease

JF - Diagnostic Microbiology and Infectious Disease

SN - 0732-8893

IS - 3

ER -